Hrncír Z, Bradna P, Nozicková H, Tichý M
II. interní klinika lékarské fakulty Univerzity Karlovy, Hradec Králové.
Vnitr Lek. 1991 Jan;37(1):63-72.
Pulsed i.v. treatment with methylprednisolone (MP) infusions à 1 g 3-5 times on alternate days was administered in 22 diffuse connective tissue diseases: 13X systemic lupus erythematosus (SLE), 1X Sharp's syndrome and 8X polymyositis/dermatomyositis (PM/DM). In all instances active disease was involved with serious organ manifestations; 17 patients had no aimed treatment so far, in 5 previous treatment had failed. A total of 101 pulsed MP was administered. Initial MP treatment was always successful. The patients were then followed up during oral maintenance treatment for 3-60 months (mean 27 months) in a stage of persistent, inconstant or partial remission. In six patients treatment was repeated 8X after reactivation. The response was always favourable and did not differ from that to initial MP treatment, except for one female patient who died from progression of PM/DM (one female patient died from the sequels of oncological disease associated with SLE).
对22例弥漫性结缔组织病患者采用静脉注射甲基强的松龙（MP）脉冲治疗，剂量为1g，隔日3 - 5次：13例系统性红斑狼疮（SLE）、1例夏普综合征和8例多发性肌炎/皮肌炎（PM/DM）。所有病例均为活动性疾病且伴有严重器官表现；17例患者此前未接受针对性治疗，5例患者先前治疗失败。共进行了101次MP脉冲治疗。初始MP治疗均获成功。随后在口服维持治疗阶段对患者进行了3 - 60个月（平均27个月）的随访，处于持续、不稳定或部分缓解阶段。6例患者病情复发后重复治疗8次。除1例死于PM/DM进展的女性患者（1例女性患者死于与SLE相关的肿瘤疾病后遗症）外，反应均良好，与初始MP治疗无异。
